Conversion of MNOK 25 Convertible Loan
Nordic Nanovector AS (“Nordic Nanovector” or the “Company”) has today received a conversion notice from HealthCap VI L.P. with respect to the convertible loan in the amount of NOK 25,000,005 made available to the Company pursuant to the subscription agreement entered into on 26 September 2013 and the resolution made by the general meeting on the same date.
The conversion price for the convertible loan is NOK 15, and the Company will accordingly issue 1,666,667 new shares to HealthCap VI L.P.
HealthCap VI L.P. shall pursuant to the subscription agreement also make an investment in the Company of NOK 25,000,000 by subscribing for new shares at a price of NOK 15 no later than 30 September 2014.
Jan A. Alfheim, CEO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 46 44 00 45
Fax: ( 47) 22 58 00 07
E-mail: jaa@nordicnanovector.no
Tone Kvåle, CFO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 91 51 95 76
Fax: ( 47) 22 58 00 07
E-mail: tkv@nordicnanovector.no
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat Non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
Tags:
